BR96-Doxorubicin: Been there, done that!

Journal of Clinical Oncology

Volumn 18, Issue 23, 2000, Pages 4000-

  Tolcher, Anthony W ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BR96 DOXORUBICIN IMMUNOCONJUGATE; BR96-DOXORUBICIN IMMUNOCONJUGATE; DOXORUBICIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

BREAST TUMOR; HUMAN; NOTE; PHASE 2 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DOXORUBICIN; HUMANS; IMMUNOTOXINS;

EID: 0034540781     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Saleh MN, Sugarman S, Murray J, et al: Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 18: 2282-2292, 2000
2. Tolcher AW, Sugarman S, Gelmon KA, et al: Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17: 478-484, 1999